<DOC>
	<DOCNO>NCT02267733</DOCNO>
	<brief_summary>A Pilot Study utilize high dose trivalent influenza vaccine dose booster dose schedule patient monoclonal gammopathy stratify disease status</brief_summary>
	<brief_title>Study High-dose Influenza Vaccine Efficacy Repeated Dosing In Gammopathy Patients</brief_title>
	<detailed_description>In study , administer FluzoneÂ® High-Dose vaccine plan booster patient monoclonal gammopathy ( stratified requirement therapy ) irrespective age . All patient receive initial vaccine follow booster vaccine 30 day ( +/- 7 day ) later follow outcome end flu season .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<criteria>Understand voluntarily sign informed consent document Age &gt; = 18 year time signing informed consent form Diagnosis monoclonal gammopathy ; Monoclonal Gammopathy Undetermined Significance ( MGUS ) , asymptomatic/ active multiple myeloma , asymptomatic / active Waldenstrom Macroglobulinemia ( WM ) An serious egg allergy prior serious adverse reaction influenza vaccine Use influenza vaccine 2014 2015 flu season Women pregnant plan become pregnant study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>